MARLBOROUGH, Mass.,
Aug. 24, 2016 /PRNewswire/ -- Hologic
Inc. (Nasdaq: HOLX) applauds Cigna's decision to cover breast
tomosynthesis for routine breast cancer screening.1
Effective immediately, this new policy provides Cigna subscribers
insurance coverage for Hologic's Genius™ 3D MAMMOGRAPHY™ exam, the
only mammogram clinically proven to detect cancer 15 months earlier
than traditional 2D screenings.2
Cigna is the first national insurer to provide coverage of 3D™
mammograms for annual breast cancer screening for all women over
age 40, and for high-risk women starting at age 25. Cigna changed
its policy based on recent guidance from the National Comprehensive
Cancer Network (NCCN), which highlighted extensive clinical
research supporting the benefits of breast tomosynthesis. With this
policy change, the Genius™ 3D MAMMOGRAPHY™ exam, shown to detect 40
percent more invasive cancers and reduce recalls by up to 41
percent, is now covered for the majority of women across
the United States.
3,4
"We commend Cigna for its decision to cover 3D™ mammograms for
breast cancer screening and are thrilled for the millions of
women who now have access to this proven technology without co-pays
or out-of-pocket expenses," said Pete
Valenti, Hologic's Division President, Breast and Skeletal
Health Solutions. "We urge other national insurers to follow
Cigna's lead, because every woman in America deserves access
to the Genius™ 3D MAMMOGRAPHY™ exam, which detects more invasive
cancers, earlier, and helps give women the best possible chance at
survival."
Genius™ 3D MAMMOGRAPHY™ exams have been available in the U.S.
since 2011, and are only available on the Hologic Selenia®
Dimensions® mammography system. More than 100 clinical studies have
proven the effectiveness of this exam and in 2015, an estimated 10
million women in the U.S. benefited from a Genius™
exam. Additional information, as well as a locator to find
imaging sites offering the exams, can be found at
http://mygenius3d.com.
About Hologic
Hologic, Inc. is a leading developer,
manufacturer and supplier of premium diagnostic products, medical
imaging systems and surgical products. The Company's core business
units focus on diagnostics, breast health, GYN surgical and
skeletal health. With a unified suite of technologies and a robust
research and development program, Hologic is dedicated to The
Science of Sure. For more information on Hologic, visit
www.hologic.com.
Hologic, 3D, 3D Mammography, Dimensions, Genius, Selenia, and
The Science of Sure are trademarks and/or registered trademarks of
Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release may
contain forward-looking information that involves risks and
uncertainties, including statements about the use of Hologic
mammography systems. There can be no assurance the systems will
achieve the benefits described here, or that such benefits will be
replicated in any particular manner with respect to an individual
patient. The actual effect of the use of the systems can only be
determined on a case-by-case basis depending on the particular
circumstances and patient in question. In addition, there can be no
assurance that the systems will achieve any expected level of sales
or market share. Hologic expressly disclaims any obligation to
release publicly any updates to the data or statements presented
here to reflect any change in the Company's expectations or any
change in events, conditions or circumstances on which any such
data or statements are based.
Media Contact:
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael
Watts
858.410.8588
michael.watts@hologic.com
1 "Cigna Revises Policy, Will
Cover 3D Mammography for Breast Cancer Screening." Cigna,
a Global Health Insurance and Health Service Company. Accessed
online 23 Aug. 2016.
2 McDonald ES, Oustimov A, Weinstein SP, et al.
Effectiveness of Digital Breast Tomosynthesis Compared With Digital
Mammography. JAMA Oncol. 2016.
3 Friedewald SM, Rafferty EA, Rose SL, et al. Breast
cancer screening using tomosynthesis in combination with digital
mammography. JAMA. 2014;311(24):2499-2507.
4 Rose SL, Tidwell AL, Bujnoch LJ, et al. Implementation
of breast tomosynthesis in a routine screening practice: an
observational study. AJR Am J Roentgenol.
2013;200(6):1401-1408.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-applauds-cigna-as-first-national-insurer-to-cover-breast-tomosynthesis-for-routine-breast-cancer-screening-300317843.html
SOURCE Hologic, Inc.